Epidemiology of pharmaceutically treated depression and treatment resistant depression in Taiwan

被引:42
作者
Fife, Daniel [1 ]
Feng, Yu [2 ]
Wang, Michael Yao-Hsien [3 ]
Chang, Chee-Jen [4 ]
Liu, Chia-Yih [5 ]
Juang, Hsiao-Ting [6 ]
Furnback, Wesley [7 ]
Singh, Jaskaran [8 ]
Wang, Bruce [7 ]
机构
[1] Janssen Pharmaceut Res & Dev LLC, Dept Epidemiol, 1125 Trenton Harbourton Rd, Titusville, NJ 08560 USA
[2] Janssen China Res & Dev Ctr, Beijing 100025, Peoples R China
[3] Buddhist Tzu Chi Gen Hosp, Taipei Branch, Dept Psychiat, New Taipei, Taiwan
[4] Chang Gung Univ, Grad Inst Clin Med Sci, 259 Wen Hwa 1st Rd, Taoyuan 333, Taiwan
[5] Chang Gung Mem Hosp, Dept Psychiat, 5 Fu Shin St, Taoyuan 33305, Taiwan
[6] Chang Gung Mem Hosp, Biostat Ctr Clin Res, 5 Fu Shin St, Taoyuan 33305, Taiwan
[7] Elysia Grp Ltd, Xiamen St,Lane 113,17-1,Floor 2, Taipei, Taiwan
[8] Janssen Pharmaceut Res & Dev LLC, Clin Res, 3210 Merryfield Row, San Diego, CA 92121 USA
关键词
Treatment resistant depression; antidepressant; medication; Incidence; Prevalence; Major depressive disorder; STAR-ASTERISK-D; RECURRENT DEPRESSION; RELAPSE PROPHYLAXIS; PARKINSON DISEASE; COGNITIVE THERAPY; DATABASE ANALYSIS; INCREASED RISK; PREVALENCE; COST; POPULATION;
D O I
10.1016/j.psychres.2017.03.006
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Epidemiologic data on treatment resistant depression (TED) in Asia-Pacific countries are limited. We estimated the incidence of TRD in Taiwan using a cohort of 704,265 adults randomly sampled from Taiwan's National Health Insurance Research database for 2005. TRD was defined as a patient having pharmaceutically treated depression (PTD) not adequately responding to 2 antidepressant (AD) regimens, i.e., AD regimens that were followed by other AD regimens. Among 2751 PTD subjects, 576 (20.94%, 95% CI: 19.46, 22.49) developed TRD, a proportion similar to that in North American studies. TRD incidence was 0.82 (95% CI: 0.75, 0.89) cases/1000 population in 2005, increased with age, and was higher in females than in males. SSRI's were the most frequently used ADs. Augmentation with antipsychotics was common. The median time from PTD onset (first AD medication) to TRD onset was 416 days but psychiatrists practicing in Taiwan indicated they would switch within < =3 months if an AD medication was not effective. We therefore repeated the analysis with a 6 months cap on time from onset of PTD to TRD. In this supplemental, post-hoc, analysis, 68 PTD subjects, 2.47%, (95% CI: 1.94, 3.10) developed TRD; i.e., 0.10 (95% CI: 0.08, 0.12) incident cases/1000 population.
引用
收藏
页码:277 / 283
页数:7
相关论文
共 46 条
  • [1] The epidemiology of major depressive episodes:: results from the International Consortium of Psychiatric Epidemiology (ICPE) Surveys
    Andrade, L
    Caraveo-Anduaga, JJ
    Berglund, P
    Bijl, RV
    De Graaf, R
    Vollebergh, W
    Dragomirecka, E
    Kohn, R
    Keller, M
    Kessler, RC
    Kawakami, N
    Kiliç, C
    Offord, D
    Ustun, TB
    Wittchen, HU
    [J]. INTERNATIONAL JOURNAL OF METHODS IN PSYCHIATRIC RESEARCH, 2003, 12 (01) : 3 - 21
  • [2] [Anonymous], PRACTICE GUIDELINE T
  • [3] [Anonymous], 2010, DEPR TREATM MAN DEPR
  • [4] Prevalence of mental, neurological, and substance use disorders in China and India: a systematic analysis
    Baxter, Amanda J.
    Charlson, Fiona J.
    Cheng, Hui G.
    Shidhaye, Rahul
    Ferrari, Alize J.
    Whiteford, Harvey A.
    [J]. LANCET PSYCHIATRY, 2016, 3 (09): : 832 - 841
  • [5] CHALLENGING THE MYTH OF AN "EPIDEMIC" OF COMMON MENTAL DISORDERS: TRENDS IN THE GLOBAL PREVALENCE OF ANXIETY AND DEPRESSION BETWEEN 1990 AND 2010
    Baxter, Amanda J.
    Scott, Kate M.
    Ferrari, Alize J.
    Norman, Rosana E.
    Vos, Theo
    Whiteford, Harvey A.
    [J]. DEPRESSION AND ANXIETY, 2014, 31 (06) : 506 - 516
  • [6] What is the meaning of treatment resistant/refractory major depression (TRD)? A systematic review of current randomized trials
    Berlim, Marcelo T.
    Turecki, Gustavo
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2007, 17 (11) : 696 - 707
  • [7] Depression relapse prophylaxis with Mindfulness-Based Cognitive Therapy: Replication and extension in the Swiss health care system
    Bondolfi, Guido
    Jermann, Francoise
    Van der Linden, Martial
    Gex-Fabry, Marianne
    Bizzini, Lucio
    Rouget, Beatrice Weber
    Myers-Arrazola, Lusmila
    Gonzalez, Christiane
    Segal, Zindel
    Aubry, Jean-Michel
    Bertschy, Gilles
    [J]. JOURNAL OF AFFECTIVE DISORDERS, 2010, 122 (03) : 224 - 231
  • [8] Cross-national epidemiology of DSM-IV major depressive episode
    Bromet, Evelyn
    Andrade, Laura Helena
    Hwang, Irving
    Sampson, Nancy A.
    Alonso, Jordi
    de Girolamo, Giovanni
    de Graaf, Ron
    Demyttenaere, Koen
    Hu, Chiyi
    Iwata, Noboru
    Karam, Aimee N.
    Kaur, Jagdish
    Kostyuchenko, Stanislav
    Lepine, Jean-Pierre
    Levinson, Daphna
    Matschinger, Herbert
    Medina Mora, Maria Elena
    Browne, Mark Oakley
    Posada-Villa, Jose
    Viana, Maria Carmen
    Williams, David R.
    Kessler, Ronald C.
    [J]. BMC MEDICINE, 2011, 9
  • [9] Impact of Treatment Success on Health Service Use and Cost in Depression Longitudinal Database Analysis
    Byford, Sarah
    Barrett, Barbara
    Despiegel, Nicolas
    Wade, Alan
    [J]. PHARMACOECONOMICS, 2011, 29 (02) : 157 - 170
  • [10] The prevalence and incidence of treated major depressive disorder among National Health Insurance enrollees in Taiwan, 1996 to 2003
    Chien, I-Chia
    Kuo, Chien-Cheng
    Bih, Shin-Huey
    Chou, Yiing-Jenq
    Lin, Ching-Heng
    Lee, Cheng-Hua
    Chou, Pesus
    [J]. CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2007, 52 (01): : 28 - 36